TY - JOUR
T1 - Treatments of AIDS-related Kaposi's sarcoma
AU - Aversa, Savina Maria Lucia
AU - Cattelan, Anna Maria
AU - Salvagno, Luigi
AU - Crivellari, Gino
AU - Banna, Giuseppe
AU - Trevenzoli, Marco
AU - Chiarion-Sileni, Vanna
AU - Monfardini, Silvio
PY - 2005/3
Y1 - 2005/3
N2 - Although Kaposi's sarcoma (KS) has decreased in countries where the highly active antiretroviral therapy (HAART) regimen is available, however it remains, after non-Hodgkin's lymphomas, the most common malignancy in HIV+ patients. Advances in the treatment of AIDS-KS have been achieved, even though a gold standard therapy has not been yet defined. With the availability of HAART, a dramatic KS clinical response has been documented, making HAART essential in all patients. In case of aggressive and/or life threatening KS, more complex therapeutic schedules have to be taken into account, including chemotherapy and/or immunotherapy. Liposomal anthracyclines and paclitaxel have been approved by FDA as first line and second line mono-therapy, respectively. Interferon-alpha (INF-α) is the only immunomodulant agent to have shown a therapeutic effect. Among the new drugs, many antiangiogenetic agents have produced encouraging responses. Finally, the identification of the HHV-8 as a causative agent and new metalloproteinase inhibitors may offer promising targets for the KS treatment.
AB - Although Kaposi's sarcoma (KS) has decreased in countries where the highly active antiretroviral therapy (HAART) regimen is available, however it remains, after non-Hodgkin's lymphomas, the most common malignancy in HIV+ patients. Advances in the treatment of AIDS-KS have been achieved, even though a gold standard therapy has not been yet defined. With the availability of HAART, a dramatic KS clinical response has been documented, making HAART essential in all patients. In case of aggressive and/or life threatening KS, more complex therapeutic schedules have to be taken into account, including chemotherapy and/or immunotherapy. Liposomal anthracyclines and paclitaxel have been approved by FDA as first line and second line mono-therapy, respectively. Interferon-alpha (INF-α) is the only immunomodulant agent to have shown a therapeutic effect. Among the new drugs, many antiangiogenetic agents have produced encouraging responses. Finally, the identification of the HHV-8 as a causative agent and new metalloproteinase inhibitors may offer promising targets for the KS treatment.
KW - AIDS-related Kaposi's sarcoma
KW - Kaposi's sarcoma
UR - http://www.scopus.com/inward/record.url?scp=13844256938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13844256938&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2004.10.009
DO - 10.1016/j.critrevonc.2004.10.009
M3 - Article
C2 - 15718150
AN - SCOPUS:13844256938
VL - 53
SP - 253
EP - 265
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 3
ER -